zidovudine and vicriviroc
zidovudine has been researched along with vicriviroc in 11 studies
Research
Studies (11)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (27.27) | 29.6817 |
2010's | 5 (45.45) | 24.3611 |
2020's | 3 (27.27) | 2.80 |
Authors
Authors | Studies |
---|---|
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
Hamatake, M; Huang, W; Komano, J; Kumakura, S; Murakami, T; Okuma, K; Tanaka, R; Tanaka, Y; Toma, J; Yamamoto, N; Yamazaki, T; Yanaka, M | 1 |
Fukushima, D; Hisaichi, K; Jenkinson, S; Kazmierski, WM; Maeda, K; Matsunaga, N; Minamoto, C; Mitsuya, H; Nakai, H; Nishiyama, T; Nishizawa, R; Sagawa, K; Shibayama, S; Tada, H; Takaoka, Y | 1 |
Fukushima, D; Hisaichi, K; Maeda, K; Minamoto, C; Mitsuya, H; Murota, M; Nakai, H; Nishiyama, T; Nishizawa, R; Sagawa, K; Shibayama, S; Tada, H; Takaoka, Y | 1 |
Chiba, J; Hashimoto, C; Komoriya, M; Murakami, T; Narumi, T; Nomura, W; Suzuki, S; Tamamura, H; Tanaka, T; Wu, H; Yamamoto, N | 1 |
Aikawa, H; Hashimoto, C; Itotani, K; Kawamata, M; Murakami, T; Narumi, T; Nomura, W; Sohma, A; Tamamura, H; Tanaka, T; Yamamoto, N | 1 |
Hashimoto, C; Komoriya, M; Mizuguchi, T; Murakami, T; Nomura, W; Ohashi, N; Tamamura, H; Yamamoto, N | 1 |
Fujino, M; Kaneko, M; Kobayakawa, T; Murakami, T; Owusu, KB; Tamamura, H; Tsuji, K; Wang, R; Yamamoto, N | 2 |
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
Angel, JB; Fätkenheuer, G; Greaves, W; Hoffmann, C; Horst, H; Landovitz, RJ; Long, J; Opravil, M | 1 |
Trials
1 trial(s) available for zidovudine and vicriviroc
Article | Year |
---|---|
Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Piperazines; Pyrimidines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2008 |
Other Studies
10 other study(ies) available for zidovudine and vicriviroc
Article | Year |
---|---|
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
Topics: Animals; Anti-HIV Agents; Calcium Signaling; Cell Line; Cells, Cultured; Chemokine CXCL12; CHO Cells; Cricetinae; Cricetulus; Fluorescent Antibody Technique; HIV Infections; HIV-1; Humans; Mice; Mice, SCID; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, CXCR4 | 2009 |
Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.
Topics: Administration, Oral; Animals; Anti-HIV Agents; CCR5 Receptor Antagonists; Cell Line, Tumor; Diketopiperazines; Drug Evaluation, Preclinical; HIV Core Protein p24; HIV-1; Humans; Microsomes, Liver; Rats; Receptors, CCR5; Spiro Compounds; Stereoisomerism | 2011 |
Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: a highly potent orally available CCR5 selective antagonist.
Topics: Administration, Oral; Animals; Anti-HIV Agents; Benzoates; CCR5 Receptor Antagonists; Diketopiperazines; Dogs; Drug Evaluation, Preclinical; Guinea Pigs; Haplorhini; Humans; Rabbits; Rats; Receptors, CCR5; Structure-Activity Relationship | 2011 |
Conjugation of cell-penetrating peptides leads to identification of anti-HIV peptides from matrix proteins.
Topics: Amino Acid Sequence; Anti-HIV Agents; Cell Membrane Permeability; Cell-Penetrating Peptides; Circular Dichroism; HeLa Cells; HIV; Humans; Models, Molecular; Molecular Sequence Data; Peptide Library | 2012 |
Pharmacophore-based small molecule CXCR4 ligands.
Topics: Anti-HIV Agents; Cell Line; HIV-1; Humans; Ligands; Oligopeptides; Receptors, CXCR4; Small Molecule Libraries; Structure-Activity Relationship; T-Lymphocytes; Virus Replication | 2012 |
Anti-HIV screening for cell-penetrating peptides using chloroquine and identification of anti-HIV peptides derived from matrix proteins.
Topics: Amino Acid Sequence; Anti-HIV Agents; Cell Line; Cell Proliferation; Cell Survival; Cell-Penetrating Peptides; Chloroquine; HIV-1; Humans; Molecular Sequence Data; Viral Matrix Proteins; Virus Internalization | 2015 |
Exploratory studies on CA-15L, an anti-HIV active HIV-1 capsid fragment.
Topics: Anti-HIV Agents; Capsid Proteins; Dose-Response Relationship, Drug; HIV; Humans; Microbial Sensitivity Tests; Molecular Structure; Peptide Fragments; Structure-Activity Relationship | 2020 |
Potent leads based on CA-19L, an anti-HIV active HIV-1 capsid fragment.
Topics: Anti-HIV Agents; Capsid Proteins; Dose-Response Relationship, Drug; HIV-1; Humans; Microbial Sensitivity Tests; Protein Conformation; Structure-Activity Relationship | 2021 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |